Wellington Management Group
ADAP

Wellington Management Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Wellington Management Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-83,302
Closed -$100K – 1893
2019
Q4 		$100K Sell
83,302
-1,513,299
-95% -$1.61M ﹤0.01% 1996
2019
Q3 		$2.41M Buy
1,596,601
+96,474
+6% +$225K ﹤0.01% 1537
2019
Q2 		$6.03M Hold
1,500,127
– – ﹤0.01% 1333
2019
Q1 		$6.45M Hold
1,500,127
– – ﹤0.01% 1317
2018
Q4 		$8.63M Hold
1,500,127
– – ﹤0.01% 1226
2018
Q3 		$20.3M Sell
1,500,127
-43,239
-3% -$453K ﹤0.01% 1079
2018
Q2 		$18.3M Buy
1,543,366
+35,401
+2% +$441K ﹤0.01% 1109
2018
Q1 		$16.9M Buy
1,507,965
+906,087
+151% +$7.93M ﹤0.01% 1125
2017
Q4 		$4.02M Sell
601,878
-15,125
-2% -$117K ﹤0.01% 1539
2017
Q3 		$5.05M Buy
617,003
+50,450
+9% +$315K ﹤0.01% 1471
2017
Q2 		$2.54M Sell
566,553
-42,080
-7% -$220K ﹤0.01% 1638
2017
Q1 		$3.35M Buy
608,633
+90,110
+17% +$394K ﹤0.01% 1597
2016
Q4 		$2.1M Sell
518,523
-55,200
-10% -$265K ﹤0.01% 1670
2016
Q3 		$4.04M Buy
573,723
+47,600
+9% +$363K ﹤0.01% 1458
2016
Q2 		$4.29M Sell
526,123
-7,520
-1% -$70.8K ﹤0.01% 1394
2016
Q1 		$4.34M Sell
533,643
-46,530
-8% -$381K ﹤0.01% 1398
2015
Q4 		$7M Buy
+580,173
New +$5.68M ﹤0.01% 1275

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group's ADAP Position: Q1 2020 in Review

Wellington Management Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2020, closing a stake of 83,302 shares — an estimated $100K sold.

Wellington Management Group first reported a position in ADAP in Q4 2015 and held it in 17 quarters. The position peaked at $20.3M in Q3 2018. 47 funds tracked by Wall St. Rank hold ADAP as of Q1 2020.

  • Wellington Management Group reported no remaining Adaptimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Wellington Management Group sold 83,302 Adaptimmune Therapeutics shares in Q1 2020, an estimated $100K.
  • Wellington Management Group first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 17 quarters.
  • Wellington Management Group's Adaptimmune Therapeutics position peaked at $20.3M in Q3 2018.
  • 47 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2020.

Based on Wellington Management Group's 13F filing for Q1 2020, filed 14 May 2020.